Giuseppe Biondi Zoccai

Slides:

Advertisements

Similar presentations

Impact of Diabetes Mellitus on Early and Long-term Results of Percutaneous Drug- eluting Stent Implantation for Unprotected Left Main Coronary Disease.

Advertisements

Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.

STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.

1 SUPERIORITY OF A HIGH CLOPIDOGREL LOADING DOSE REGIMEN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: EVIDENCE FROM A META-ANALYSIS G. BIONDI-ZOCCAI1,

PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY ON THE MANAGEMENT OF INTERMEDIATE CORONARY STENOSES: The Functional or morphological Lesion Assessment for.

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

A Systematic Review On The Hazards Of Aspirin Discontinuation Among Patients With Or At Risk For Coronary Artery Disease Giuseppe Biondi Zoccai Hemodynamics.

Elective Stenting versus Balloon Angioplasty with Bail-out Stenting for Small Vessel Coronary Artery Disease: Evidence from a Meta-analysis of Randomized.

Tips and tricks for performing standard meta-regression analysis with SPSS Giuseppe Biondi Zoccai Division of Cardiology, Department of Internal Medicine,

Applications of bivalirudin in interventional cardiology

1 SIROLIMUS-ELUTING STENTS FOR IN-STENT RESTENOSIS TREATMENT IN 278 UNSELECTED PATIENTS: INSIGHTS ON LONG-TERM OUTCOMES FROM A LARGE TWO-CENTER REGISTRY.

Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

Title1 Brain Natriuretic Peptide Levels Have A Significant Prognostic Role In Patients With Suspected Or Confirmed Acute Pulmonary Embolism: Evidence From.

PCI vs. CABG: Review of the evidence and suggestions Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Giuseppe Biondi Zoccai Division of Cardiology University of Turin, Turin Critical aspects of trials on the new generation DES 31st.

Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.

Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.

LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,

1 HIGH CLOPIDOGREL LOADING DOSE IS SUPERIOR TO A STANDARD 300 MG REGIMEN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: EVIDENCE FROM A META-ANALYSIS.

Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy JOINT SYMPOSIUM WITH JACCT - Bologna, 25/9/2008.

Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.

1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

4 th European Bifurcation Club September PRAGUE A comprehensive meta- analysis on drug-eluting stenting for unprotected left main disease.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,

Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:

The BVS-SAVE Italian registry: Bioresorbable Vascular Scaffolds

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Primer on Adjusted Indirect Comparison Meta-Analyses

Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.

Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,

The American College of Cardiology Presented by Dr. Maurits T. Dirksen

Background There is ongoing debate to identify the most effective drug-eluting stent between the two currently most used devices (ie, sirolimus- [SES]

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

European Society of Cardiology 2003

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.

Giuseppe Biondi Zoccai, MD

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Nat. Rev. Cardiol. doi: /nrcardio

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY.

P. Omedé,1 A. Abbate,4 G. P. Trevi,1 and I. Sheiban1

The American College of Cardiology Presented by Dr. Raimund Erbel

SURGERY EARLY AFTER DES IMPLANTATION

Benefits of complete coronary revascularization – Counterpoint: what are you talking about? Giuseppe Biondi Zoccai, MD University of Modena and Reggio.

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

Figure 4 Observational studies on multiple treatment strategies

PREDICTORS OF ADVERSE EVENTS IN PATIENTS WITH UNPROTECTED LEFT MAIN DISEASE TREATED WITH DRUG-ELUTING STENTS: EVIDENCE FROM A COLLABORATIVE META-REGRESSION.

CHRONIC TOTAL OCCLUSIONS: WHAT IS KNOWN AND

BENEFITS OF CLOPIDOGREL IN PATIENTS UNDERGOING CORONARY STENTING SIGNIFICANTLY DEPEND ON LOADING DOSE: EVIDENCE FROM A SYSTEMATIC REVIEW AND META-REGRESSION.

Single Versus Multiple Vessel Stenting In Patients With St-Elevation Myocardial Infarction: Results From A 30,886-Patient Meta-Analysis Giuseppe Biondi.

ORAL CILOSTAZOL TREATMENT PREVENTS RESTENOSIS AND MAJOR ADVERSE CLINICAL EVENTS AFTER DRUG-ELUTING STENT IMPLANTATION: EVIDENCE FROM A META-ANALYSIS G.

Nat. Rev. Cardiol. doi: /nrcardio

Comparison of radial versus femoral access in patients undergoing invasive management for acute coronary syndromes: evidence from a systematic review and.

Maintenance of Long-Term Clinical Benefit with

Is Prasugrel Superior To Ticagrelor For The Treatment Of Patients With Acute Coronary Syndromes? Evidence From A 32,893-Patient Adjusted Indirect Comparison.

(A) Meta-analysis of repeat revascularisation in randomised trials.

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

The American College of Cardiology Presented by Dr. A. Abazid

TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Presentation transcript:

Giuseppe Biondi Zoccai Culprit-only versus multivessel percutaneous coronary intervention for multivessel disease in patients with st-elevation myocardial infarction: evidence from a 30,886-patient meta-analysis Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy

Background and Aim There is uncertainty on the most appropriate management of patients with acute Stelevation myocardial infarction (STEMI) and concomitant multivessel coronary artery disease. We thus performed a systematic review and meta-analysis comparing a culprit-only vs. multivessel percutaneous coronary intervention (PCI) in this setting.

Methods Pertinent controlled clinical studies including 30 or more patients and comparing a culprit-only vs. multivessel PCI strategy in patients with STEMI were systematically searched in several databases. The primary end-point was the rate of major adverse cardiac events (MACE, i.e. the composite of death, recurrent myocardial infarction, or repeat revascularization). Secondary end-points included individual components of MACEs. Risk differences (RD, with 95% confidence intervals) were computed using random-effect methods.

Results From a total of 687 citations, 10 clinical trials were shortlisted (with only 1 randomized study), including 30,886 patients with STEMI and concomitant multivessel disease, treated with a culprit-only vs. multivessel PCI, and followed for a median of 12 months after discharge. Meta-analytic pooling showed similar 12-month rates of MACEs (RD=-3% [-9%; +3%], p=0.33), death (RD=-1% [-3%; +1%], p=0.23), recurrent myocardial infarction (RD=-2% [-8%; +3%], p=0.40,) or repeat revascularization (RD=0% [-6%; 5%], p=0.88).

Results After an average follow-up of 24±15 months, unadjusted rates of MACE were 17.7% vs. 16.4%, with death in 2.7% vs 4.9%, myocardial infarction in 4.4% vs. 3.7%, TLR in 15.0% vs. 12.3%, and stent thrombosis in 3.1% vs. 2.7% (all p>0.05). Even at extensive multivariable analysis with propensity adjustment, IVUS guidance was not associated with any statistically significant impact on the risk of MACE, death, myocardial infarction, TLR (neither on the main branch nor on the side branch), or stent thrombosis (all p>0.05).

Risk of major adverse cardiac events

Risk of death

Risk of myocardial infarction

Risk of repeat revascularization

Conclusions Despite the fact that multivessel coronary disease detrimentally impacts on the prognosis of STEMI patients, a culprit-only revascularization strategy should be sought after in most cases, unless patient instability or symptoms/signs of residual myocardial ischemia clearly support non-culprit vessel intervention.

Thank you for your attention For any correspondence: gbiondizoccai@gmail.com For these and further slides on these topics feel free to visit the metcardio.org website: http://www.metcardio.org/slides.html